Lirioresinol B Dimethyl Ethers Inhibits CCL4-induced Chronic Inflammation and Cell Dysplasia by Preventing NF-kB Expression

Abstract

Inflammation is considered one of the key components in the initiation and progression of Hepatocellular carcinoma (HCC). Upon failure to eliminate Inflammation causing factors which induce acute inflammation, leads to cause chronic inflammation, cell dysplasia, and ultimately cancer. To prevent liver cancer, inflammatory mediators were targeted for inhibition of chronic liver inflammation and liver cell dysplasia in this study. Lirioresinol B Dimethyl ether is an anti-inflammatory phytochemical that was used to modulate expression levels of NF-kB and I-kB. NF-kB is a transcription factor responsible for transcription of inflammatory genes and anti-apoptotic proteins while I-kB is inhibitory protein that inhibits activation and nuclear translocation of NF-kB. Western blot results of this study show that Lirioresinol B Dimethyl Ether down-regulated NF-kB and up-regulated expression levels of I-kB in hepatocytes of experimental group treated with Lirioresinol B Dimethyl Ether. ALT and ALP levels and histopathology results also present that Lirioresinol B Dimethyl ether significantly inhibits chronic liver inflammation and liver cell Dysplasia and prevents cancer development by regulating NF-kB/I-kB activation.